Plesa A, Roumier C, Gutrin J, Larcher M-V, Balsat M, Cadassou O, Barraco F, Fossard G, Baudouin A, Labussière H, et al. Measurable residual disease including AML leukemia stem cell flow evaluation of CPX-351 therapy by multi-parameter flow cytometry. Leuk Res. 2021;111:106673.